Advances in immune-based therapies of renal cell carcinoma
Authors:
- John S LamJLJohn S Lam
- Arie S BelldegrunABArie S Belldegrun
- Robert A FiglinRFRobert A Figlin
- 1 December 2004
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 4 (6) , 1081-1096
Abstract
Renal cell carcinoma (RCC) is the most prevalent malignancy within the kidney, and over 40% of patients with RCC will die from their disease. Approximately a third of patients present with metastatic disease and a third of patients undergoing nephrectomy for clinically localized RCC will develop metastases. Metastatic RCC poses a therapeutic challenge due to its resistance to conventional modes of therapy such as chemotherapy and radiation therapy. While it is clear that strides have been made against metastatic RCC, the overall objective response rates of interleukin-2- and interferon-alpha-based immunotherapy remain at approximately 20%. Despite advances in biologic- and immune-based therapies, long-term survival for patients with metastatic RCC remains modest. Furthermore, the toxicity profile of these cytokine regimens is significant. Advances in the understanding of the nature of tumor antigens and their optimal presentation, and in the regulatory mechanisms that govern the immune system, have provided multiple novel immunotherapy intervention strategies with increased specificity and potentially fewer side effects. Such strategies are currently being tested in clinical trials.Keywords
This publication has 43 references indexed in Scilit:
- Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell CancerJournal of Clinical Oncology, 2004
- Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined AnalysisJournal of Urology, 2004
- Interferon Alfa-2b Three Times Daily and Thalidomide in the Treatment of Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2003
- Phase I trial of interferon α2b and liposome‐encapsulated all‐trans retinoic acid in the treatment of patients with advanced renal cell carcinomaCancer, 2002
- Interaction of Retinoic Acid and Interferon in Renal Cancer Cell LinesJournal of Interferon & Cytokine Research, 2000
- Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and Bacillus Calmette-Guèrin: Five-year results of a prospective randomized studyCancer, 1996
- Characterization of Tumor-Infiltrating Lymphocyte Subsets from Human Renal Cell Carcinoma: Specific Reactivity Defined by Cytotoxicity, Interferon-?? Secretion, and ProliferationJournal of Immunotherapy, 1994
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- Autologous Tumor-Specific Cytotoxicity of Tumor-Infiltrating Lymphocytes Derived from Human Renal Cell CarcinomaJournal of Immunotherapy, 1991
- Renal cell carcinoma treated by vaccines for active specific immunotherapy: Correlation of survival with skin testing by autologous tumor cellsCancer Immunology, Immunotherapy, 1990